U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07069569) titled 'A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs' on June 25.
Brief Summary: This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Chronic Hepatitis B
Intervention:
DRUG: AHB-137 and Peg-IFN
AHB-137 will be injected (16 weeks ). Peg-IFN will be administered.
DRUG: AHB-137 and Peg-IFN
AHB-137 will be injected (24 weeks). Peg-IFN will be administered .
DRUG: AHB-137 and ...